2021.10.16 19:28 hlaiie Your professor ever talk about something for forty minutes, fills the board, and ends it with: “But anyways, none of that will be on the test.”
2021.10.16 19:28 Meravion I started accessing a4 in full voice (at least i think so). Yay
Im a bit excited as I wondered if I will ever be able to reach it. I still had some head room on it and could hit it a bit harder. It is mixed voice, right? Hopefully Ill be able to use it in songs soon
submitted by Meravion to singing [link] [comments]
2021.10.16 19:28 jnwosu100 It seems Xiao Mei has other abilities like immortality and limited reality warping?
2021.10.16 19:28 Classic_Purpose_3034 who is the toughest in the Caucasus?
the Caucasus is full of tough guys and has an over emphasis on being macho. but who is the toughest? i would say chechens but they seem more insane than tough
submitted by Classic_Purpose_3034 to AskCaucasus [link] [comments]
2021.10.16 19:28 Brilliant_Mode3927 w2c good quality? or the black ones
|submitted by Brilliant_Mode3927 to sneakerreps [link] [comments]|
2021.10.16 19:28 DkG4 Does anybody know, which Half-Life map is this?
| Is this playable in some version of the game? Maybe alpha or some pre-release? This was part of multiple screenshots strip (link below) available from site included in Uplink demo promoting full game. Other screenshots looks interesting too.|
Thanks for the info!
submitted by DkG4 to HalfLife [link] [comments]
2021.10.16 19:28 UnstableScotsman I never understood complaints about bugs. Until now.
Finish 1 lap down...
...despite crossing the line in 2nd? With no penalties?
submitted by UnstableScotsman to F1Game [link] [comments]
2021.10.16 19:28 Robinjo1985 Friends fear NYC art-world heiress is isolated by daughter
2021.10.16 19:28 FatFaceRikky Schneeberg von Wien aus gesehen
|submitted by FatFaceRikky to wien [link] [comments]|
2021.10.16 19:28 MinaHarker1 Calling it the “China virus,” no less
|submitted by MinaHarker1 to HermanCainAward [link] [comments]|
2021.10.16 19:28 Skyline_Z900RS Tatsumaki and Fubuki have some kind of flammes on their clothes in the databook illustration
|submitted by Skyline_Z900RS to OnePunchMan [link] [comments]|
2021.10.16 19:28 Olawuyialabi5 Mine
|submitted by Olawuyialabi5 to LordArenaOfficial [link] [comments]|
2021.10.16 19:28 eg-likar-potet Which one should I choose?
|submitted by eg-likar-potet to FortniteSavetheWorld [link] [comments]|
2021.10.16 19:28 The_Majestic_ 'You could say this has shifted the dial': How Super Saturday was won
|submitted by The_Majestic_ to CoronavirusDownunder [link] [comments]|
2021.10.16 19:28 owlitup Pokemon has the monopoly on the monster catching genre because of us
I played Nexomon lately and it hit me. I like Pokemon, but I always wondered why no one could make another similar game like it. Like, Metroid influenced tons of other metroidvanias for example, but we never had a true competitor to this franchise.
Pokemon has its flaws and games like Nexomon address some of them. I played it at a friends house and we both enjoyed the game. But then no one else is playing it. You can't trade or battle with people. They can put whatever mechanics, graphics or monster into a game, but Pokemon has us, the players, doing the in-game collecting thing in real life with each other. That's what makes it. The monster catching genre has a real-life social aspect that is essential to be as enjoyable as it is. I put maybe 50 hours into Pokemon campaigns all in all and probably 200 more socializing with people IRL or online.
And this isn't some unjust Pokemon monarchy either. The franchise has earned its place through two decades of nonstop successful media. That's how it gets ya. You can enjoy Nexomon or whatever game, but you can't make the next Pokemon because you need to build that brand awareness. They've been building it for 20 years
that's my saturday morning take
submitted by owlitup to pokemon [link] [comments]
2021.10.16 19:28 Immediate_Question99 💟 MINI BITCOIN CASH 💟 Stealth Launch 💟 Listed On PancakeSwap 💟 Liquidity locked 💟
💟 💟 💟 💟 💟 💟 💟 💟 💟 💟 💟 💟 💟 💟 💟 💟
✅ WELLCOM TO MINI BITCOIN CASH (MBCash/BNB) ✅
🚀 5 minutes ago FAİRLAUNCH 🚀
✅ Token MINI BITCOIN CASH is funded solely through its own cryptocurrency, a BEP20 token leveraging a smart contract on the Binance Block Chain network. ✅
• ✅ DOXXED FOUNDERS
• ✅ ANTI WHALE MECHANICS
• ✅ ANTI BOT PROTOCOL
• ✅ WHITEPAPER
• ✅ LIVE AMA
❇️ Pancake Swap : https://exchange.pancakeswap.finance/#/swap?outputCurrency=0x0bfbec4e6021122370df0c6ff4041adbfa8020ef
❇️ Honeypot: Zero TX
❇️ Deeplock: Lock LP 180 Days
🎯 We set out below some key points for you to consider choosing us:
- No Pre Sale, No Air Drop, Just Stealth Launch
- Total Supply: 1.000.000.000
- No dev wallet (Dev will also buy at start)
- Ownership Renounced
- Liquidity Locked 100%
- No dev wallet (Admins will also buy after launch and keep feeding the liquidity if it is necessary)
🎯 We are sick of it aswell it, so we have created our own token and dedicated it to all those that have been scammed so get in early and don’t miss out!
We will make sure this token is safe and a good investment for all, with great rewards to our early holders...
submitted by Immediate_Question99 to SatoshiBets [link] [comments]
2021.10.16 19:28 SelfAwareMachine Anticholinergic drugs cause dementia, lead to worse outcomes than those not taking them.
Anticholinergic drugs are among the most widely prescribed class of drugs today, used in the treatment of conditions from motion sickness to psychosis. Of the two 200 most prescribed drugs, a significant portion of them are Anticholinergic. I have limited the following studies to within the last two years, honestly because it was too depressing to dig any deeper.
Do Anticholinergic drugs cause dementia?:
Anticholinergic Drug Exposure and the Risk of DementiaA Nested Case-Control Study
There were significant increases in dementia risk for the anticholinergic antidepressants (adjusted OR [AOR], 1.29; 95% CI, 1.24-1.34), antiparkinson drugs (AOR, 1.52; 95% CI, 1.16-2.00), antipsychotics (AOR, 1.70; 95% CI, 1.53-1.90), bladder antimuscarinic drugs (AOR, 1.65; 95% CI, 1.56-1.75), and antiepileptic drugs (AOR, 1.39; 95% CI, 1.22-1.57) all for more than 1095 TSDDs.Increased risk of incident dementia following use of anticholinergic agents: A systematic literature review and meta-analysis
Anticholinergic use for ≥3 months increased the risk of dementia on average by an estimated 46% versus nonuse. This relationship was consistent in studies assessing overactive bladder medications. The risk of developing dementia should be carefully considered in the context of potential benefit before prescribing anticholinergics.Dose response relationship of cumulative anticholinergic exposure with incident dementia: validation study of Korean anticholinergic burden scale
This study confirmed the dose response relationship for cumulative anticholinergic burden measured using the Korean specific anticholinergic burden scale with incident dementia.Anticholinergic drugs and the risk of dementia: A systematic review and meta-analysis
After pooling fourteen longitudinal and case-control studies with a total of 1,564,181 subjects, anticholinergic drug use was associated with an increased risk of all-cause dementia and Alzheimer's disease. Both low and high anticholinergic drug burdens were associated with dementia. Moreover, there was a dose-dependent relationship between anticholinergic drugs and risk of dementia. With respect to the categories of anticholinergic drugs, antiparkinson, urological drugs, and antidepressants increased the risk for dementia; however, cardiovascular and gastrointestinal drugs played potentially protective roles.Anticholinergic drugs and incident dementia, mild cognitive impairment and cognitive decline: a meta-analysis
Anticholinergic drug use, particularly long-term use, is associated with greater incidence of dementia and cognitive decline.Anticholinergic medications and risk of dementia in older adults: Where are we now?
The review demonstrates moderate to strong risk of dementia with anticholinergic use in multiple studies involving older adults, irrespective of the study design, analytical approach, anticholinergic exposure and outcome definition. This risk is particularly significant with the cumulative burden and high-level anticholinergics. There also exists a dose-response relationship between anticholinergic use and increased risk for dementia. Therefore, anticholinergic agents can be considered as a modifiable risk factor for dementia and cognitive decline in older adults.Are anticholinergics harmful to individuals with the conditions they are prescribed for?
Participants with schizophrenia not on antipsychotics after the first 2 years have better outcomes than participants prescribed antipsychotics. Even when the confound by indication for prescribing antipsychotic medication is controlled for, participants with schizophrenia and affective psychosis do better than their medicated cohorts, strongly confirming the importance of exposing the role of aiDSP and antipsychotic drug resistance.Five-Year Cumulative Exposure to Antipsychotic Medication After First-Episode Psychosis and its Association With 19-Year Outcomes
After adjustment for confounders, moderate and high cumulative exposure to antipsychotics within the first 5 years from FEP was consistently associated with a higher risk of adverse outcomes during the 19-year follow-up, as compared to low or zero exposure.Cognitive burden of anticholinergic medications in psychotic disorders
Anticholinergic burden aggregated across all medications was inversely related to cognitive performance starting at ADS scores of 4 in participants with schizophrenia.Long-term antipsychotic use and cognitive decline in community-dwelling older adults with mild–moderate Alzheimer disease: Data from NILVAD
Long-term antipsychotic use was associated with greater cognitive decline and dementia progression in community-dwelling older adults with mild–moderate AD.Anticholinergic Medication Burden–Associated Cognitive Impairment in Schizophrenia
Anticholinergic medication burden in schizophrenia is substantial, common, conferred by multiple medication classes, and associated with cognitive impairments across all cognitive domains. Anticholinergic medication burden from all medication classes–including psychotropics used in usual care–should be considered in treatment decisions and accounted for in studies of cognitive functioning in schizophrenia.The Impact of Anticholinergic Burden on Functional Capacity in Persons With Schizophrenia Across the Adult Life Span
In conclusion, people with schizophrenia are exposed to severe ACB that can have a direct negative impact on functional capacity after controlling for its impact on cognition. Reducing ACB could improve functional capacity and potentially real-world function in schizophrenia.The effect of anticholinergic burden on cognitive and daily living functions in patients with schizophrenia
Our analysis shows that anticholinergic burden reduces cognitive and daily living functions in patients with schizophrenia. A drug strategy with minimal anticholinergic burden may be helpful to patients if it does not adversely affect clinical symptoms.Anticholinergic Burden Measures Predict Older People's Physical Function and Quality of Life: A Systematic Review
The evidence supports association between increased ACB and future impairments in physical function and quality of life.Consistency between anticholinergic burden scales in the elderly with fractures
The ACB scale identified the highest anticholinergic burden (26.8%) in prescriptions made the month before the fracture, and the highest agreement was between ACB and ADS (0.717); during hospitalization and at discharge, the cholinergic antagonists were best identified with ADS (77.7% and 72.1%, respectively), with the best agreement between ACB and ARS (0.613 and 0.568, respectively). The prescription of tramadol was found in 64.1% of hospitalized patients and in 61.4% of patients at the time of discharge.Adverse Effects of Anticholinergic Drugs on Cognition and Mobility: Cutoff for Impairment in a Cross-Sectional Study in Young-Old and Old-Old Adults
Drugs with anticholinergic (antimuscarinic) properties are associated with cognitive impairment in individuals as young as 55 years, and only one such drug per day, regardless of its anticholinergic burden, is associated with both impaired cognition and impaired mobility in old-old adults. Therefore, wherever possible, clinicians should avoid prescribing drugs with anticholinergic properties.A meta-analysis of observational studies on anticholinergic burden and fracture risk: evaluation of conventional burden scales
This result suggests that the relationship between anticholinergic drug burden and fracture risk may differ depending on the anticholinergic burden scale used.Anticholinergics May Carry Significant Cognitive and Gait Burden in Parkinson's Disease
Patients with PD are exposed to significant anticholinergic burden from drugs prescribed for PD and non-PD indications. Higher anticholinergic burden is associated with cognitive impairment and FOG even in younger patients with PD.Association between Anticholinergic Medication Use and Risk of Dementia among Patients with Parkinson's Disease
Among patients with Parkinson's disease in Taiwan, those with a high cumulative dose of anticholinergics had an increased risk of being diagnosed with dementia. Physicians should consider prescribing the lowest therapeutic dose of anticholinergic medication when making treatment decisions for patients with Parkinson's disease.Do anticholinergics cause delirium and increase mortality?: Effect of anticholinergic burden on treatment modification, delirium and mortality in newly diagnosed dementia patients starting a cholinesterase inhibitor: A population-based study
This study showed that high anticholinergic burden negatively affected the treatment response to cholinesterase inhibitors and that an average ACB score />/3 was an independent prognostic factor for delirium or mortality in dementia patients.Autonomic nervous system dysfunction in schizophrenia: impact on cognitive and metabolic health
The strongest association of low heart rate variability was noted among patients on antipsychotic treatment with high-affinity muscarinic antagonism (i.e., clozapine, olanzapine and quetiapine).Are doctors more wary about anticholinergics now that the risk of dementia is understood?:
Anticholinergic medication use is linked with increased cognitive decline, dementia, falls and mortality, and their use should be limited in older people. Use of potent anticholinergic medications nearly doubled in England's older population over 20 years with some of the greatest increases amongst those particularly vulnerable to anticholinergic side-effects.Increase in anticholinergic burden from 1990 to 2015: Age-period-cohort analysis in UK biobank
Anticholinergic burden in the sample increased up to 9-fold over 25 years and was observed for both period and age effects across most classes of drugs. The greatest increase was seen in the prescribing of antidepressants. Female sex, lower education and greater deprivation were associated with greater anticholinergic burden.Are medical professionals aware of the risk of anticholinergic drugs?:
A total of 74% participants admitted to have no understanding of the term ACB, 48% participants prescribe anticholinergics in their daily role, 44% knew that cognition was adversely affected by anticholinergics, and 16% participants were aware of scoring system. Only 16% participants routinely counsel women of cognitive side effects when anticholinergics are started. 86% reported that they would avoid prescribing medications which might affect cognition if possible. If given choice as a patient, 94% would avoid these medications if they were informed of the specific side effects like impaired cognition, physical decline, falls, hospital admissions and increased mortality.Are anticholinergic prescriptions being adequately screened for interactions?:
In a representative sample of outpatient visits, polypharmacy was extremely common among PWD, driven by a wide array of medication categories.https://pubmed.ncbi.nlm.nih.gov/34349978/
Inappropriate medication prescriptions are associated with impaired physical function across longitudinal and cross-sectional studies in older adults situated in diverse settings.An overview of prevalence, determinants and health outcomes of polypharmacy
Our review showed that the prevalence of polypharmacy varied between 10% to as high as around 90% in different populations. Chronic conditions, demographics, socioeconomics and self-assessed health factors were independent predictors of polypharmacy. Polypharmacy was reported to be associated with various adverse outcomes after adjusting for health conditions.Is there a consistent way to determine risk from Anticholinergic drugs?
The scales evaluated show marked discrepancies between them, with highly variable frequencies of anticholinergic drugs identified at the different prescription times, and with low agreement among them, which is why the scales are not interchangeable in patients with bone fractures.Anticholinergic Drug Burden and Delirium: A Systematic Review
ADB assessed with the ARS is consistently associated with delirium.Are Anticholinergic drugs effective treatments?:
The 20-year data indicate that, longitudinally, after the first few years, antipsychotic medications do not eliminate or reduce the frequency of psychosis in schizophrenia, or reduce the severity of post-acute psychosis, although it is difficult to reach unambiguous conclusions about the efficacy of treatment in purely naturalistic or observational research. Longitudinally, on the basis of their psychotic activity and the disruption of functioning, the condition of the majority of SZ prescribed antipsychotics for multiple years would raise questions as to how many of them are truly in remission.submitted by SelfAwareMachine to remodeledbrain [link] [comments]
2021.10.16 19:28 jahid2017 Gistcoin project overview.
Gistcoin project will have succeeded in near future and many people will support this project. The team is trustworthy. Are you buying.This is one of the most interesting project in the virtual world. So,don't miss buy this GISTCOIN from sale stage for every investors. https://gistcoin.io/
gistcoin #clubhouse #gisthouse #gisthouseaudioapp #erc20tokens #Defi #crowdsale #altcoin #NFT submitted by jahid2017 to ico [link] [comments]
2021.10.16 19:28 No-Pay370 AYYYliens Minting Soon link in comments
|submitted by No-Pay370 to NFT [link] [comments]|
2021.10.16 19:27 Mirkutea [FOR HIRE] Anime style art starting at $15 only
2021.10.16 19:27 GreenFIREtoasT "travel" underwear?
They're always quite expensive, and you can't really try before you buy. Is there a brand or product for 'travel' underwear that you swear by - or will never buy again?
submitted by GreenFIREtoasT to travel [link] [comments]
2021.10.16 19:27 mistermasterman People who were in love with someone they couldn’t be with, what did you do? [serious]
2021.10.16 19:27 Hairyfrenchtoast Natalie Portman & Keira Knightley
|submitted by Hairyfrenchtoast to totallylookslike [link] [comments]|
2021.10.16 19:27 Better_Rocket Here you go, sir
|submitted by Better_Rocket to meme [link] [comments]|
2021.10.16 19:27 radagans mammoth coins
hello everyone! long time no see yall, some months ago (2 months i think ) i was talking about the collectors pack and what it comes with it, and yesterday i bought the collectors pack, and i spend 500 coins, 420 to finish the battle pass and i got 20 as one of the rewards of the bp and i had 100 remaining and i opened a synthwave box, now i got 3000 coins and i got no idea of what to do with it, should i buy some skins that i want or keep it for events/future bp?
submitted by radagans to Brawlhalla [link] [comments]